Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for ELI Lilly & Co and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$1,444.80+1.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 29, 2026
Lilly discovers, makes, and sells prescription medicines for diseases including diabetes, obesity, cancer, and inflammatory conditions.
Company outlook: revenue of $91B to $92B for Fiscal year 2026 — up 40.4% on a year earlier